Cargando…
Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease
There is mounting evidence for a role of the growth factor granulocyte-macrophage colony-stimulating factor (GM-CSF) in inflammatory disease, including arthritis. In the present study, we examined the effectiveness of treatment of collagen-induced arthritis (CIA) with a neutralizing mAb to GM-CSF. D...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC64841/ https://www.ncbi.nlm.nih.gov/pubmed/11549370 |
_version_ | 1782120152896110592 |
---|---|
author | Cook, Andrew D Braine, Emma L Campbell, Ian K Rich, Melissa J Hamilton, John A |
author_facet | Cook, Andrew D Braine, Emma L Campbell, Ian K Rich, Melissa J Hamilton, John A |
author_sort | Cook, Andrew D |
collection | PubMed |
description | There is mounting evidence for a role of the growth factor granulocyte-macrophage colony-stimulating factor (GM-CSF) in inflammatory disease, including arthritis. In the present study, we examined the effectiveness of treatment of collagen-induced arthritis (CIA) with a neutralizing mAb to GM-CSF. DBA/1 mice were immunized for the development of CIA and treated at different times, and with different doses, with neutralizing mAb to GM-CSF or isotype control mAb. Anti-GM-CSF mAb treatment prior to the onset of arthritis, at the time of antigen challenge, was effective at ameliorating the ensuing disease. Modulation of arthritis was seen predominantly as a reduction in overall disease severity, both in terms of the number of limbs affected per mouse and the clinical score of affected limbs. Importantly, anti-GM-CSF mAb treatment ameliorated existing disease, seen both as a reduction in the number of initially affected limbs progressing and lower numbers of additional limbs becoming affected. By histology, both inflammation and cartilage destruction were reduced in anti-GM-CSF-treated mice, and the levels of tumor necrosis factor-a and IL-1? were also reduced in joint tissue washouts of these mice. Neither humoral nor cellular immunity to type II collagen, however, was affected by anti-GM-CSF mAb treatment. These results suggest that the major effect of GM-CSF in CIA is on mediating the effector phase of the inflammatory reaction to type II collagen. The results also highlight the essential role of GM-CSF in the ongoing development of inflammation and arthritis in CIA, with possible therapeutic implications for rheumatoid arthritis. |
format | Text |
id | pubmed-64841 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2001 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-648412002-01-25 Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease Cook, Andrew D Braine, Emma L Campbell, Ian K Rich, Melissa J Hamilton, John A Arthritis Res Research Article There is mounting evidence for a role of the growth factor granulocyte-macrophage colony-stimulating factor (GM-CSF) in inflammatory disease, including arthritis. In the present study, we examined the effectiveness of treatment of collagen-induced arthritis (CIA) with a neutralizing mAb to GM-CSF. DBA/1 mice were immunized for the development of CIA and treated at different times, and with different doses, with neutralizing mAb to GM-CSF or isotype control mAb. Anti-GM-CSF mAb treatment prior to the onset of arthritis, at the time of antigen challenge, was effective at ameliorating the ensuing disease. Modulation of arthritis was seen predominantly as a reduction in overall disease severity, both in terms of the number of limbs affected per mouse and the clinical score of affected limbs. Importantly, anti-GM-CSF mAb treatment ameliorated existing disease, seen both as a reduction in the number of initially affected limbs progressing and lower numbers of additional limbs becoming affected. By histology, both inflammation and cartilage destruction were reduced in anti-GM-CSF-treated mice, and the levels of tumor necrosis factor-a and IL-1? were also reduced in joint tissue washouts of these mice. Neither humoral nor cellular immunity to type II collagen, however, was affected by anti-GM-CSF mAb treatment. These results suggest that the major effect of GM-CSF in CIA is on mediating the effector phase of the inflammatory reaction to type II collagen. The results also highlight the essential role of GM-CSF in the ongoing development of inflammation and arthritis in CIA, with possible therapeutic implications for rheumatoid arthritis. BioMed Central 2001 2001-06-11 /pmc/articles/PMC64841/ /pubmed/11549370 Text en Copyright © 2001 Cook et al, licensee BioMed Central Ltd |
spellingShingle | Research Article Cook, Andrew D Braine, Emma L Campbell, Ian K Rich, Melissa J Hamilton, John A Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease |
title | Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease |
title_full | Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease |
title_fullStr | Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease |
title_full_unstemmed | Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease |
title_short | Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease |
title_sort | blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (gm-csf): requirement for gm-csf in the effector phase of disease |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC64841/ https://www.ncbi.nlm.nih.gov/pubmed/11549370 |
work_keys_str_mv | AT cookandrewd blockadeofcollageninducedarthritispostonsetbyantibodytogranulocytemacrophagecolonystimulatingfactorgmcsfrequirementforgmcsfintheeffectorphaseofdisease AT braineemmal blockadeofcollageninducedarthritispostonsetbyantibodytogranulocytemacrophagecolonystimulatingfactorgmcsfrequirementforgmcsfintheeffectorphaseofdisease AT campbelliank blockadeofcollageninducedarthritispostonsetbyantibodytogranulocytemacrophagecolonystimulatingfactorgmcsfrequirementforgmcsfintheeffectorphaseofdisease AT richmelissaj blockadeofcollageninducedarthritispostonsetbyantibodytogranulocytemacrophagecolonystimulatingfactorgmcsfrequirementforgmcsfintheeffectorphaseofdisease AT hamiltonjohna blockadeofcollageninducedarthritispostonsetbyantibodytogranulocytemacrophagecolonystimulatingfactorgmcsfrequirementforgmcsfintheeffectorphaseofdisease |